Taysha Doses Second Patient With Rett Syndrome With TSHA-102

The second patient has been dosed in the phase 1/2 REVEAL clinical trial evaluating Taysha Gene Therapies’ TSHA-102, an investigational adeno-associated virus (AAV) vector-based gene therapy, for the treatment of adult patients with Rett syndrome.

“Dosing the second adult patient in the REVEAL phase 1/2 adult trial in Canada marks important progress in the ongoing clinical evaluation of TSHA-102 for Rett syndrome,” Sukumar Nagendran, MD, the president and head of research and development, at Taysha, said in a statement.